M&R Capital Management Inc. maintained its stake in Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,650 shares of the medical research company’s stock at the end of the second quarter. M&R Capital Management Inc.’s holdings in Amgen were worth $403,000 at the end of the most recent reporting period.
A number of other large investors also recently added to or reduced their stakes in the stock. Oakworth Capital Inc. increased its position in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares during the period. Glassman Wealth Services increased its position in shares of Amgen by 480.0% in the second quarter. Glassman Wealth Services now owns 725 shares of the medical research company’s stock worth $110,000 after buying an additional 600 shares during the period. Integrated Wealth Management increased its position in shares of Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock worth $141,000 after buying an additional 3 shares during the period. Delta Asset Management LLC TN increased its position in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares during the period. Finally, Capital Advisors Ltd. LLC increased its position in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.
Amgen Inc. (NASDAQ:AMGN) opened at 167.34 on Tuesday. Amgen Inc. has a 52 week low of $138.06 and a 52 week high of $176.85. The company has a market cap of $125.23 billion, a P/E ratio of 17.12 and a beta of 0.94. The firm has a 50-day moving average price of $171.51 and a 200 day moving average price of $161.44.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, topping analysts’ consensus estimates of $2.74 by $0.10. The firm earned $5.69 billion during the quarter, compared to analyst estimates of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.57 earnings per share. Analysts expect that Amgen Inc. will post $11.36 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th were paid a $1.00 dividend. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.39%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s dividend payout ratio (DPR) is 40.90%.
A number of research analysts have issued reports on AMGN shares. Vetr downgraded Amgen from a “buy” rating to a “hold” rating and set a $159.50 price objective for the company. in a research note on Tuesday, June 7th. Bank of America Corp. restated a “hold” rating and issued a $182.00 price objective on shares of Amgen in a research note on Wednesday, June 8th. BMO Capital Markets restated an “outperform” rating and issued a $186.00 price objective on shares of Amgen in a research note on Thursday, June 9th. Leerink Swann restated a “market perform” rating and issued a $186.00 price objective on shares of Amgen in a research note on Thursday, June 9th. Finally, Goldman Sachs Group Inc. restated a “buy” rating and issued a $202.00 price objective on shares of Amgen in a research note on Wednesday, June 15th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $185.06.
In other news, VP Annette Louise Such sold 3,000 shares of the company’s stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.20% of the stock is owned by insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.